BioCity Biopharma Reports the P-II (2-SUCCEED) Study Data of SC0062 to Treat IgA Nephropathy
Shots:
- BioCity reported the results from P-II (2-SUCCEED) study for the safety & efficacy of SC0062 vs PBO to treat CKD, with 2 parallel arms of IgAN & diabetic kidney disease (DKD). DKD study is underway with results anticipated in Q4’24
- Study reached the 1EP in IgAN, demonstrating proteinuria reduction with a clear dose-response relationship, without retaining fluid & a favorable safety; good safety outcomes were also observed with SC0062 + SGLT2 inhibitors among patients on SGLT2 inhibitors in the study. Data will be highlighted at future conferences
- SC0062, an ETA antagonist for CKD, is developed to improve renal blood flow, reduce proteinuria, inflammation & fibrosis as well as alleviate the AE of fluid retention
Ref: BioCity | Image: BioCity
Related News:- BioCity Collaborated with AstraZeneca to Evaluate BC3402 + Imfinzi (durvalumab) for Advanced Hepatocellular Carcinoma in China
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.
